Neurocrine Biosciences — Jul 30, 2025 release

sults Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA ® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY ® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO , July 30, 2025 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance. “As we begin our transition into a new chapter of growth and diversification for Neurocrine, we’re pleased with our second quarter commercial performance across tardive dyskinesia, Huntington’s chorea, and now, classic congenital adrenal hyperplasia,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “Although still early in our launch, the demand for CRENESSITY remains robust, underscoring the significant unmet need for a novel treatment option for patients with CAH.” Dr. Gano added, “With revenue contributions from both INGREZZA and CRENESSITY along with our strong balance sheet, we are well-positioned to advance and expand our neuropsychiatry pipeline, including our ongoing registrational programs in major depressive disorder with osavampator and in schizophrenia with NBI-’568, our selective M4 muscarinic agonist.” Net Product Sale